These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25514168)

  • 1. Eruptive nevi and hair depigmentation related to regorafenib.
    Sibaud V; Munsch C; Lamant L
    Eur J Dermatol; 2015; 25(1):85-6. PubMed ID: 25514168
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib in metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
    [No Abstract]   [Full Text] [Related]  

  • 3. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer.
    Sugita K; Kawakami K; Yokokawa T; Mae Y; Toya W; Hagino A; Suzuki K; Suenaga M; Mizunuma N; Yamaguchi T; Hama T
    Anticancer Res; 2015 Jul; 35(7):4059-62. PubMed ID: 26124355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
    Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
    Draper A
    Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
    [No Abstract]   [Full Text] [Related]  

  • 8. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
    Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
    Mitchell J; Khoukaz T; McNeal D; Brent L
    Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.
    Wong AL; Lim JS; Sinha A; Gopinathan A; Lim R; Tan CS; Soh T; Venkatesh S; Titin C; Sapari NS; Lee SC; Yong WP; Tan DS; Pang B; Wang TT; Zee YK; Soong R; Trnkova Z; Lathia C; Thiery JP; Wilhelm S; Jeffers M; Goh BC
    J Transl Med; 2015 Feb; 13():57. PubMed ID: 25889309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A closer look at regorafenib.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Oct; 16(10):667-669. PubMed ID: 30543596
    [No Abstract]   [Full Text] [Related]  

  • 13. Bilateral sensorineural hearing loss induced by regorafenib.
    Cheng J; Wang L; Zhu LN; Wang L
    J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigation of Administration Technique of Regorafenib in Our Center].
    Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
    Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
    Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma].
    Mihara Y; Yamaguchi K; Nakama T; Nakayama G; Kamei H; Ishibashi N; Uchida S; Akagi Y; Ogata Y
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):233-6. PubMed ID: 25743146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
    Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment on: "Regorafenib: Start Low and Go Slow".
    de la Fouchardière C
    Target Oncol; 2016 Feb; 11(1):123-5. PubMed ID: 26634250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.